Patent Application
20200197349
The present invention relates to compositions for use in improving the cognitive function of adult human subjects, and more especially for use in elderly subjects (65 years or older), and in particular in elderly subjects who are cognitively healthy for their age. The invention also relates to methods of improving or maintaining the cognitive function of adult human subjects.
Concomitant with the growing population and increases in life expectancy in most regions is the increasing prevalence of age-related diseases. Dementia represents the most significant stage of cognitive decline and is one of the fastest growing age-related diseases. Estimates suggest that there are over 52 million adults worldwide with dementia, with prevalence numbers expected to double every 20 years (Alzheimer's Disease International, 2018). Dementia poses one of the greatest health care challenges of our society in terms of personal, societal and financial implications. Current pharmacological interventions for Alzheimer's disease (AD), the most common form of dementia, are aimed at neurochemical imbalance and have limited success in stabilising or slowing the progression of the disease. Thus, emphasis is being placed on strategies to promote healthy ageing, with the aim of minimising the burden of disability and disease in later life and maximising the quality of life for individuals in their later years.
Alzheimer's disease is the most common type of dementia, followed by vascular dementia. In the UK, the number of people with AD at present is around 860,000 and in the USA is about 5.6 million. With increasing age and population, it is anticipated that the overall prevalence of the disease will continue to increase. Despite considerable research effort, the cause of the disease is still unknown but established risk factors include age, family history of disease and education [Alzheimer's Association (2017) 2017 Alzheimer's disease facts and figures, Alzheimer's Association, Chicago, Ill., USA] and putative risk factors include cigarette smoking, physical inactivity and social isolation [Livingstone et al., (2017) Dementia prevention, intervention, and care. Lancet 390, 2673-2734]. The effectiveness of current pharmacological treatments (medications) is strictly limited and varies among individuals. Moreover, the effect of current medications is at best only palliative, as they cannot halt disease progression. The UK NHS suggests, as preventative, the following: cessation of smoking, limiting alcohol consumption, a healthy well balanced diet, and staying physically and mentally active.
There have been numerous studies on the effects of the Mediterranean Diet, a diet characterised by a high intake of vegetables, olive oil, and a moderate intake of fish, dairy products and wine. There is a consensus that adherence to such diets is associated with better cognitive performance [see e.g.: Tangney et al., (2011) Adherence to a Mediterranean-type dietary pattern and cognitive decline in a community population. Am J Clin Nutr 93, 601-607; Feart et al., (2009) Adherence to a Mediterranean diet, cognitive decline, and risk of dementia. J.A.M.A. 302, 638-648; Trichopoulou et al., (2015) Mediterranean diet and cognitive decline over time in an elderly Mediterranean population. Eur. J Nutr. 54, 1311-1321; Pelletier et al., (2015) Mediterranean diet and preserved brain structural connectivity in older subjects. Alzheimers Dement 11, 1023-1031; McEvoy et al., (2017) Neuroprotective Diets Are Associated with Better Cognitive Function: The Health and Retirement Study. J IAm Geriatr Soc 65, 1857-1862; and Lourida et al., (2013) Mediterranean diet, cognitive function, and dementia: a systematic review. Epidemiology 24, 479-489] and a reduced risk of dementia, especially AD [see e.g.: Psaltopoulou et al., (2013) Mediterranean diet, stroke, cognitive impairment, and depression: A meta-analysis. Ann. Neurol 74, 580-591; Singh et al., (2014) Association of Mediterranean diet with mild cognitive impairment and Alzheimer's disease: a systematic review and meta-analysis. J Alzheimers Dis 39, 271-282; Scarmeas et al., (2006) Mediterranean diet and risk for Alzheimer's disease. Ann Neurol 59, 912-921; Scarmeas et al., (2009) Mediterranean diet and mild cognitive impairment. Arch Neurol 66, 216-225; and Sofi et al., (2014) Mediterranean diet and health status: an updated meta-analysis and a proposal for a literature-based adherence score. Public Health Nutr 17, 2769-2782], but no clear evidence of the exact foodstuffs responsible.
Some studies have pointed to an effect from omega-3 fatty acids, of which docosahexaenoic acid (DHA) is found in high concentration in fish oil and in fatty fish such salmon and herring. There is a substantial concentration of DHA in the human brain where it forms a structural component within this neural tissue. High consumption of omega-3 fatty acids is associated with better cognitive performance and a reduced risk of dementia (see Muldoon et al., (2014) Long-chain omega-3 fatty acids and optimization of cognitive performance. Mil Med 179, 95-105; Cole et al., (2005) Prevention of Alzheimer's disease: Omega-3 fatty acid and phenolic anti-oxidant interventions. Neurobiol Aging 26 Suppl 1, 133-136; Fotuhi et al., (2009) Fish consumption, long-chain omega-3 fatty acids and risk of cognitive decline or Alzheimer disease: a complex association. Nat Clin Pract Neurol 5, 140-152; Thomas et al., (2015) Omega-3 Fatty Acids in Early Prevention of Inflammatory Neurodegenerative Disease: A Focus on Alzheimer's Disease. Biomed Res Int 2015, 172801; and Cole & Frautschy et al., (2010) DHA may prevent age-related dementia. J Nutr 140, 869-874]. However, interventional studies have shown conflicting results, with some demonstrating improvements in cognition [see Abubakari et al., (2014) Omega-3 fatty acid supplementation and cognitive function: are smaller dosages more beneficial? Int J Gen Med 7, 463-473 and Yurko-Mauro et al., (2010) Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimers Dement 6, 456-464], and others demonstrating no beneficial effect [see Phillips et al., (2015) No Effect of Omega-3 Fatty Acid Supplementation on Cognition and Mood in Individuals with Cognitive Impairment and Probable Alzheimer's Disease: A Randomised Controlled Trial. Int J Mol Sci 16, 24600-24613, and van de Rest et al., (2008) Effect of fish oil on cognitive performance in older subjects: a randomized, controlled trial. Neurology 71, 430-438].
Other food items of interest include the carotenoids lutein (L) and zeaxanthin (Z). These carotenoids, which are of dietary origin are found in certain fruits and vegetables (e.g. spinach, broccoli, peppers, melon). In humans, L and Z are found in high concentrations in the eye (specifically the centre part of the retina known as the macula, where they are referred to as “macular pigment” or “macular carotenoids”) and brain [Johnson et al., (2013) Relationship between Serum and Brain Carotenoids, alpha-Tocopherol, and Retinol Concentrations and Cognitive Performance in the Oldest Old from the Georgia Centenarian Study. J Aging Res 2013, 951786; and Craft et al., (2004) Carotenoid, tocopherol, and retinol concentrations in elderly human brain. J Nutr Health Aging 8, 156-162]. High carotenoid intake has been found to result in a reduced risk of AD [Feart et al., (2016) Plasma Carotenoids Are Inversely Associated With Dementia Risk in an Elderly French Cohort. J Gerontol A Biol Sci Med Sci 71, 683-688; Min & Min (2014) Serum lycopene, lutein and zeaxanthin, and the risk of Alzheimer's disease mortality in older adults. Dement Geriatr Cogn Disord 37, 246-256; and Loef & Walach (2012) Fruit, vegetables and prevention of cognitive decline or dementia: a systematic review of cohort studies. J Nutr Health Aging 16, 626-630]. Some studies administering L and Z have shown improvement in different domains of cognition [Hammond et al., (2017) Effects of Lutein/Zeaxanthin Supplementation on the Cognitive Function of Community Dwelling Older Adults: A Randomized, Double-Masked, Placebo-Controlled Trial. Front Aging Neurosci 9, 254; and Johnson et al., (2008) Cognitive findings of an exploratory trial of docosahexaenoic acid and lutein supplementation in older women. Nutr Neurosci 11, 75-83], while another randomised trial showed no benefit [Chew et al., Age-Related Eye Disease Study 2 Research G (2015) Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation].
Another macular carotenoid is meso-zeaxanthin (MZ), which is a stereoisomer of zeaxanthin. The chemical structures of L, Z and MZ are shown in
Vitamin E is also present in the brain, and high plasma concentrations of vitamin E have been associated with a reduced risk of AD (Mangialasche et al., (2010) High plasma levels of vitamin E forms and reduced Alzheimer's disease risk in advanced age. J Alzheimers Dis 20, 1029-1037). There have been no reports of successful treatment of AD following administration of this vitamin.
In summary, there is general agreement that there are substances in the brain which might possibly play a role in preventing in cognitively healthy subjects AD, but attempts so far to identify or use them have been unsuccessful.
Compositions comprising all three macular carotenoids (L, Z and MZ) are commercially available as nutritional supplements. One example of such a supplement is sold under the trade mark MacuPrime®, and consists of capsules containing the three macular s carotenoids L, Z and MZ in the amounts of 10 mg, 2 mg and 10 mg, respectively, per capsule. WO 2013/005037 discloses the use of such a composition for improving the visual performance of a human subject, the composition optionally further comprising a fish oil and/or an omega 3 fatty acid.
US2016/0067203 (Lion Corporation) discloses and claims compositions for improving cognitive function, the compositions comprising docosahexaenoic acid (DHA) in combination with lutein, zeaxanthin and capsanthin. The specification includes the results of a “Passive Avoidance Test” performed using mice fed the test composition or a control composition for 3 months (see especially Example 5 in Table 2 of the prior art document). The mice were given a mild electric shock when they went into a darkened compartment, and learned to avoid the darkened compartment when the test was repeated. The prior art specification also presents data (Table 3) suggesting that the amount of amyloid P protein in the brain was reduced in the test mice compared to the controls (although the numbers of animals involved in this experiment were very small, n=3 and n=4), so these results are not statistically significant.
There are no data from experiments with human subjects. Also, there is no evidence that the exemplified composition could improve cognitive function in, or stabilise the condition of, subjects already suffering from cognitive impairment.
WO2006/16755 (Trustees of Tufts College) discloses and claims a composition having “synergistic amounts of lutein and DHA for use in improvement of cognitive function”. The claims are based on a trial in which 50 human subjects (all female) were given daily supplements, over a 4 month period, containing (i) a placebo; or (ii) DHA or lutein; or (iii) DHA and lutein in combination. Various cognitive function tests were performed at start and end of the period of supplementation, and the results are shown in Table 2 of the prior art document. All compositions, except the placebo, gave statistically significant (<0.05) improvements in a verbal fluency test (hence, there was no evidence of any synergy between the DHA and lutein).
In addition however, subjects given the DHA/lutein combination demonstrated statistically significant improvements in a Shopping List Memory Test and an MIR (“Memory-in-Reality”) Apartment Test. However for the latter, it is clear from FIG. 4 of the prior art publication that the baseline score was unusually low for that group, so a big improvement was perhaps nothing to do with the supplementation. Finally, there is no evidence to show that the DHA/lutein combination could have any positive effect on subjects already experiencing cognitive impairment.
WO2019/110591 discloses the use of a composition comprising lutein, zeaxanthin, meso-zeaxanthin, and at least one omega-3 fatty acid for use in the treatment of dementia in a human subject. Specifically, the data presented in the document show that a group of patients with Alzheimer's disease, when given a dietary supplement containing the composition, were more likely to demonstrate an improvement in cognitive function or to demonstrate less deterioration in cognitive function, compared to an age-matched control group of Alzheimer's disease patients who were not given the dietary supplement.
There are several systems commercially available for testing of cognitive function (Zygouris & Tsolak, 2015).
One method of assessing cognitive function is to use the RBANS tests (“Repeatable Battery for the Assessment of Neuropsychological Status”). The RBANS protocol tests five domains of cognition: immediate memory, visuospatial ability, language, attention, and delayed memory, using 12 sub-tests. The RBANS takes about 30 minutes to administer and is a core diagnostic tool for detecting and characterising dementia (Randolph et al., 1998 “The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity” J Clin Exp NeuropsychoL 20(3) 310-319).
A computerised system is the CANTAB Connect Research software, available from Cambridge Cognition (www.cambricecognition.com; Tunbridge Court, Bottisham, Cambridge CB25 9TU, UK; and Cambridge Innovation Center, One Broadway, Cambridge, Mass. 02142, USA). This system comprises a battery of tests which are intended to target various specific domains of cognition: comprehension; executive function (working memory); reaction time; and episodic memory. The system includes four different tasks, which are referred to in the Cambridge Cognition publications (Cambridge Cognition 2016a, b) as MOT, SWM, RTI and PAL. These tests are designed to interrogate the four specific domains noted above. Thus MOT test targets comprehension, the SWM test interrogates working memory, the RTI test targets reaction time, and the PAL test interrogates episodic memory. The tests can be performed using a tablet computer with a touch screen, and require a finger-operated response.
The SWM (Spatial Working Memory task measures the ability to retain spatial information and manipulate it in working memory. SWM is a measure of the pre-frontal cortex brain region. In this task, the individual is presented with some boxes on the screen. The aim is to find the tokens that are hidden inside the boxes. Only one token will be hidden at a time.
Individuals must search for tokens by touching the coloured boxes (with the index finger of their dominant hand) to open them. The task becomes more difficult as the number of boxes (and tokens to find) increases. The key task instruction is that the tokens will never appear in the same box twice, so the individual must not return to a box if they have already found a token in that box. If the individual returns to a box where they have already found a token it will be classed as an error. If the individual first opens a box that is empty, they may return to that box again as a token could appear in that box at a later stage (e.g. the second or third time that they return to that box, depending on the difficulty level of the task). Importantly, when they first find a token in a box they must remember not to return to that box. Essentially, the individual must remember the location of the box in which they have or have not found a token during each level of the task.
The individual completes two practice rounds prior to commencing the SWM task. In each of the practice rounds, the individual must collect a total of three tokens. There are three levels of increasing difficulty for this task; stage 4 where the individual must locate four tokens in total—4 boxes appear on the screen at any one time, and only one of the 4 boxes will contain a token at a given time; stage 6 where the individual must locate six tokens in total (with 6 boxes on screen at any one time); and stage 8 where the individual must locate eight tokens in total (with 8 boxes on screen at any one time).
The task measures cognitive function by calculating the number of errors made by an individual in performing the task. The software recognises several categories of error:
Again the “Total Errors” can be calculated for each individual stage (4, 6 or 8), or a combined total for all three stages.
Other computer-based systems for measuring cognitive function are available and are reviewed by Zygouris & Tsolaki (cited elsewhere) and include, for example: CANS-MCI (Computer-Administered Neuropsychological Screen for Mild Cognitive Impairment) and CAMCI (Computer Assessment of Mild Cognitive Impairment, available from Psychology Software Tools, Inc. Pittsburgh, Pa. 15215, USA).
The content of all citations is incorporated herein by reference.
In a first aspect the invention provides a method of improving the cognitive function of a cognitively healthy human adult, the method comprising administering to the human adult an effective amount of a composition comprising lutein, zeaxanthin, meso-zeaxanthin and at least one omega-3 fatty acid, over a period of at least 12 months, preferably at least 24 months, the improved cognitive function being a detectable improvement in: spatial working memory as measured by the CANTAB Connect Research software SWM task; and/or reduced reaction time as measured by the CANTAB Connect Research Software RTI task.
For present purposes, a human adult is considered “cognitively healthy” if they fulfil the following criteria: no self or family member reported memory loss; no rapidly progressive or fluctuating symptoms of memory loss; no established diagnosis of early dementia; and a score of 26 or higher in the Montreal Cognitive Assessment (MoCA) version 7.1 (Nasreddine et al., 2005; Luis, Keegan & Mullin, 2009).
Preferably a cognitively healthy human adult will also have an “immediate memory score” of 100 or more, as measured by the RBANS test (Randolph et al., 1998, cited above).
Preferably the method is performed on a mature subject (i.e. 65 years old or more).
In a second aspect, the invention provides a composition comprising lutein, zeaxanthin and meso-zeaxanthin and at least one omega-3 fatty acid, for use in improving the is cognitive function of a cognitively healthy human adult, the improvement in cognitive function being a detectable improvement in spatial working memory, as measured by the CANTAB Connect Research software SWM task; and/or reduced reaction time as measured by the CANTAB Connect Research Software RTI task.
The CANTAB Connect Research Spatial Working Memory (SWM) test requires retention and manipulation of visuospatial information. This self-ordered test has notable executive function demands and allows measurement of working memory errors.
The inventors have found that, in particular, the cognitive function of subjects is improved compared to control subjects when the difficulty of the task is increased. Thus, for example, at stage 6 and, more especially, at stage 8 of the SWM task, subjects who had been consuming the nutritional supplement in accordance with the invention made statistically significantly fewer errors than control subjects.
For the purposes of the present application, an improvement in spatial working memory is preferably detected by a reduction in the number of “Total Errors” made by the subject at stage 8 (“TE8”), or across all stages (“TE 4-8”) of the SWM test taken following consumption of the composition over the defined period of at least 12 months, preferably at least 24 months, (the test being taken within one week of the end of the defined period), compared to the total number of errors made by the subject across all the stages of the SWM test taken prior to commencing consumption of the composition. Preferably the total number of errors is reduced by 2 or more, more preferably by an amount in the range 3-5. Alternatively, the total number of errors is preferably reduced by at least 15%, more preferably by at least 20%, and most preferably by an amount in the range 20-25%.
The CANTAB Connect Research Reaction Time (RTI) test allows assessment of motor and mental response speeds, as well as measurement of movement time, reaction time and response accuracy. In the test, the subject must select and hold a button at the bottom of a computer tablet screen. Circles are presented above (one circle for the simple mode; and five circles for the five-choice made). In each case, a yellow dot will appear in one of the circles, and the subject must react as soon as possible, releasing the button at the bottom of the screen, and selecting the circle in which the dot appeared.
Outcome measures are divided into reaction time and movement time for both the simple and five choice variants.
In the present invention, it is preferred that the parameter selected for measurement is the reaction time in the ‘simple’ format test, and a detectable improvement in the reaction time is preferably detected by a reduction in the simple reaction time of the subject in the RTI test taken following consumption of the composition over the defined period of at least 12 months (the test being taken within one week of the end of the defined period), compared to the simple reaction time of the subject in the RTI test taken prior to commencing consumption of the composition. Desirably the simple reaction time of the subject is reduced by at least 10 milliseconds, preferably by at least 15 milliseconds, and desirably by an amount in the range 15-20 milliseconds. Alternatively stated, the simple reaction time is preferably reduced by at least 3%, more preferably at least 4%, and most preferably by an amount in the range 4.5-5.5%.
Preferably, in the first and second aspects of the invention, consumption of the composition by the subject for the defined period results in a detectable performance improvement in both the SWM test and the RTI test.
In the first or second aspect of the invention, the composition may be administered by any suitable route to a human subject including, for example, intra-venous administration. Preferably however the composition is administered orally, and advantageously the composition is formulated so as to be suitable for oral administration.
As noted previously, the composition comprises at least one omega-3 fatty acid. For present purposes, unless the context dictates otherwise, the term “fatty acid” is intended also to encompass not only the free acid but also derivatives of fatty acids, such derivatives encompassing in particular esters, especially esters formed with glycerol (monoglycerides, diglycerides and, preferably, triglycerides), and salts. Preferred salts are those containing monocations, such as Na+, K+ or NH4+. Most preferred salts are those comprising metallic monocations. The free fatty acid or the triglyceride is the most preferred form of the compound.
The omega-3 fatty acid component of the composition preferably comprises an omega-3 polyunsaturated fatty acid or derivative thereof; most preferably docosahexaenoic acid (DHA) or a derivative thereof. The composition may contain two or more omega-3 fatty acids. The composition may comprise eicosapentaenoic acid (EPA). In one embodiment the composition comprises both DHA and EPA.
A convenient source of omega-3 fatty acids is fish oil. Accordingly, in a preferred embodiment, the composition comprises fish oil. Since fish oil has quite a strong odour, it may be preferred to use deodorized fish oil, which is commercially available. Another source of omega-3 fatty acids is nut oil. Without being bound by any particular theory, the inventors believe that DHA is the most active omega-3 fatty acid in terms of preventing and/or treating dementia. Nut oil does not contain substantial amounts of DHA and therefore is not preferred for the purposes of the present invention.
Other sources of fatty acids include algae (see Ji et al, 2015 “Omega-3 Biotechnology: A green and sustainable process for omega-3 fatty acids production” Front Bioeng. Biotechnol. 3, 158).
The composition may be formulated in a ‘bulk’ form, to be admixed, for example, with a conventional foodstuff, including dairy foodstuffs (e.g. incorporated into butter or ice cream) or non-diary foodstuffs (e.g. margarine, vegetable stock or fish-stock preparations). More preferably however the composition is formulated in unit dosage form, preferably one suitable for oral consumption by a human subject, including a tablet, capsule, gel, liquid, powder or the like. The one or more macular carotenoids may be granulated, for example as microcapsules, before inclusion in the formulation.
Conveniently, but not necessarily, the composition may be packaged in a foil blister pack, of the sort known to those skilled in the art. Desirably one or two of the doses are taken each day, the amount of active agents in the doses being adjusted accordingly.
The composition may conveniently comprise conventional diluents, especially vegetable oils such as sunflower, safflower, corn oil and rape seed oils, excipients, bulking agents and the like which are well known to those skilled in the art. Such substances include, calcium and/or magnesium stearate, starch or modified starch.
Other conventional formulating agents may be present in the composition, including any one or more of the following non-exhaustive list: acidity regulators; anticaking agents (e.g. sodium aluminosilicate, calcium or magnesium carbonate, calcium silicate, sodium or potassium ferricyanide), antioxidants (e.g. vitamin E, vitamin C, polyphenols), colorings (e.g. artificial colorings such as FD&C Blue No. 1, Blue No. 2, Green No. 3, Red No. 40, Red No. 3, Yellow No. 5 and Yellow No. 6; and natural colorings such as caramel, annatto, cochineal, betanin, turmeric, saffron, paprika etc.); color retention agents; emulsifiers; flavours; flavour enhancers; preservatives; stabilizers; sweeteners and thickeners.
Other optional ingredients of the composition include vitamins and/or minerals. Preferably the composition comprises vitamin E. Preferably the composition comprises at least one B vitamin. Preferably the composition comprises vitamin E and at least one B vitamin.
Typically the composition is administered at least once a week, preferably at least twice a week, more preferably three times a week, and most preferably daily. In a typical embodiment at least one unit dosage form of the composition is taken on a daily basis. The person skilled in the art will appreciate that the frequency of consumption can be adjusted to take account of the concentration of active agents (the macular carotenoids, and omega-3 fatty acid), present in the formulation. The administration of the composition can be adjusted accordingly.
In order to obtain optimum effect, the composition should be administered, typically at least 2 or 3 times a week, and preferably daily, over a period of at least 6 months, preferably over a period of at least 12 months, more preferably over a period of at least 18 months and most preferably over a period of 24 months. If desired, the composition may be administered indefinitely, for as long as the subject is able to consume or otherwise receive the composition.
For present purposes the “active agents” in the composition are considered to be the macular carotenoids and the at least one omega-3 fatty acid.
The precise concentration of the active agents in the composition of the invention is not critical: a beneficial effect on the subject can be obtained by consuming larger doses of a composition comprising lower concentrations of active agents, or vice versa.
The composition includes three macular carotenoids, and their respective ratio in the composition is not thought to be critical and can vary quite widely. For example, the percentage of either MZ or lutein in the composition can range from 10% to 90% (of the macular carotenoid present in the composition). The percentage of zeaxanthin can typically range from about 5 to 45% (of the macular carotenoid present in the composition). One particular composition has an MZ:lutein:zeaxanthin ratio of 10:10:2 (or 45%, 45%, 10%), but this is not essential. Another typical composition has a ratio (MZ:L:Z) of 12:10:2.
One preferred composition for use in performance of the invention is in unit dosage form, with each unit dose comprising 2 mgs meso-zeaxanthin, 18 mgs lutein and 2 mgs zeaxanthin (i.e. an MZ:L:Z ratio of 2:18:2). The composition preferably further comprises fish oil as a source of omega-3 fatty acid. Desirably each unit dose comprises 0.5-1.0 gram of fish oil.
Another composition for use in performance of the invention is in unit dosage form, with each unit dose comprising 10 mgs meso-zeaxanthin, 10 mgs lutein, 2 mgs zeaxanthin and fish oil (preferably 1 gm of fish oil).
Another composition for use in performance of the invention is in unit dosage form with each unit dose comprising 15 mgs meso-zeaxanthin, 5 mgs lutein, 1 mg zeaxanthin and fish oil (preferably 1 gm fish oil).
These doses may conveniently be presented as capsules. As the resulting capsules are quite large, and possibly difficult to swallow for elderly subjects, the unit dose may, for example, be halved and the subject thus swallows two such capsules in order to obtain the desired dose of active agents.
In one particular embodiment, the composition substantially consists of lutein, zeaxanthin, meso-zeaxanthin and fish oil, surrounded by an inert capsule material. Suitable materials for use as a capsule material are well-known to those skilled in the art and include, inter alia, gelatin and cellulose-derived polymers such as hypromellose.
Desirably an average daily dose of the composition provides a total macular carotenoid content of up to, but not exceeding, 100 mg, preferably up to, but not exceeding, 75 mg, and most preferably up to, but not exceeding, 50 mg. Desirably the average daily dose of the composition provides a minimum total macular carotenoid content of at least 18 mg, more preferably at least 20 mg, and most preferably at least 22 mg. Such concentrations are known to be well-tolerated with substantially no adverse effects.
Advantageously, the average daily dose of the composition provides an amount of omega-3 fatty acid in the range 10 mg to 2 gms, more preferably in the range 20 mgs to 2 gms, and most preferably in the range 25 mgs to 1 gram.
The foregoing omega-3 fatty acid content may be provided entirely by DHA, or by a combination of two or more omega-3 fatty acids, one of which is preferably DHA. DHA desirably constitutes at least 50% of the omega-3 fatty acid content of the composition, preferably at least 55%, more preferably at least 60%, and most preferably at least 65% of the omega-3 fatty acid content of the composition.
The various aspects and features of the invention will now be further described by way of illustrative embodiment and with reference to the following drawing figures, in which:
The inventors organised a parallel group, double-blind, placebo-controlled randomised clinical trial to investigate the impact of nutritional supplementation on cognitive function in cognitively healthy, mature (≥65 years of age) adults.
Concomitant with the growing population and increases in life expectancy in most regions is the increasing prevalence of age-related diseases. Dementia represents the most significant stage of cognitive decline and is one of the fastest growing age-related diseases. Estimates suggest that there are over 52 million adults worldwide with dementia, with prevalence numbers expected to double every 20 years (Alzheimer's Disease International, 2018). Dementia poses one of the greatest health care challenges to society in terms of personal, societal and financial implications. Current pharmacological interventions for AD, the most common form of dementia, are aimed at neurochemical imbalance and have limited success in stabilising or slowing the progression of the disease. Thus, emphasis is being placed on strategies to promote healthy ageing, with the aim of minimising the burden of disability and disease in later life and maximising the quality of life for individuals in their later years.
Accumulating evidence from observational and interventional studies suggests that good nutrition (e.g. fruits, vegetables and fish) can positively impact on cognition and AD risk. Advances in science and technology have increased our capacity to fully elucidate the unique neuroprotective mechanisms of specific nutrients that are likely to be driving the positive results that have been observed between good nutrition and healthy cognitive status. Given the abundance of ω-3 FAs in the brain, the selective presence of xanthophyll carotenoids and vitamin E in brain tissue, and their ability to independently and synergistically attenuate the mechanisms involved in the pathogenesis of AD (namely oxidative damage and inflammation), it is likely that they play a significant neuro-protective role by maintaining and optimising cognition and reducing the risk of cognitive s decline. However, well designed and appropriately powered interventional trials are needed to confirm this hypothesis. The Cognitive impAiRmEnt Study (CARES) was a parallel group, double-blind, placebo-controlled, randomised clinical trial studying two populations of interest. This trial (CARES Trial 1) investigated the impact of targeted nutritional supplementation on cognitive function in cognitively healthy older adults (≥65 years).
CARES trial 1 investigated the impact of 24-month supplementation with xanthophyll carotenoids, ω-3FAs and vitamin E on cognitive function in cognitively healthy older adults. Volunteers, primarily from the South-East of Ireland, were recruited through regional and national advertisement campaigns. Eligibility criteria for CARES included: aged ≥65 years; no self or family member reported memory loss; no rapidly progressive or fluctuating symptoms of memory loss; no established diagnosis of early dementia; no consumption of cognitive enhancement therapy such as cholinesterase inhibitors or N-methyl-D-aspartate receptor antagonists); no stroke disease (clinical stroke or stroke on CTB); no depression (under active review); no psychiatric illness (under active review of psychotropic medications); no glaucoma (acute angle); not consuming carotenoid or fish/cod liver oil supplements; and no fish allergy.
Prior to enrolment, all individuals completed a screening assessment to confirm eligibility. This included assessing cognitive function using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Record Form A and the Montreal Cognitive Assessment (MoCA) version 7.1. A description of each of these assessments is provided below. Individuals that fulfilled the criteria for each cognitive and functional assessment were invited to participate in the clinical trial. Individuals with borderline scores from the screening assessments were referred to a consensus panel (via email or conference call) consisting of two Consultant Geriatricians and a Clinical Neuropsychologist for assessment of eligibility (Albert et al., 2011; Dubois & Albert, 2004). Eligible individuals were then invited to enrol into the study. Prior to enrolment, written informed consent was obtained from all individuals. Ethical approval was granted by the Research Ethics Committees of the Waterford Institute of Technology and University Hospital Waterford in Waterford, Ireland. CARES (trial registration number. ISRCTNI0431469) adhered to the tenets of the declaration of Helsinki and followed the full code of ethics with respect to recruitment, testing and general data protection regulations as set out by the European Parliament and Council of the European Union.
Eligible individuals were randomised to either the active intervention group, which received a supplement containing 10 mg L; 10 mg MZ; 2 mg Z; 15 mg vitamin E (a-tocopherol); 1 g fish oil (of which 430 mg DHA and 90 mg EPA) or placebo (sunflower oil) intervention group. These doses were provided via two oval-size capsules. Individuals were instructed to consume two capsules per day with a meal. Frequent phone calls were made to ensure compliance. Tablet counting was also performed at follow-up. Study visits occurred at baseline, 12- and 24-months at a single site (Nutrition Research Centre Ireland [NRCI]). The trial commenced in March 2016 and concluded in June 2019 (i.e. last 24-month subject visit). Intervention randomisation was performed by an electronic trial management system (Trial Controller) designed by the inventors and their colleagues. This administration system was also used to document patient information (name and contact details), support the organisation and management of capsules required for the clinical trial and assist with the scheduling of study visits. The primary outcome measure of CARES was change in cognitive function. Secondary outcome measures (explained in greater detail below) included change in the following variables: macular pigment optical volume (MPOV); visual function; serum xanthophyll carotenoid concentrations; serum vitamin E concentrations; and plasma ω-3FA concentrations.
The MoCA was used at the screening stage to assess global cognition. It is a short (10 minute) cognitive screening tool with high sensitivity and specificity for detecting MCI (Luis, Keegan, & Mullan, 2009; Nasreddine et al., 2005). Thirty items assess multiple cognitive domains including visuospatial abilities, executive function, phonemic fluency, attention, immediate and delayed recall, language and orientation. In the present study, a score 226 was desirable for enrolment. The RBANS was used to measure global cognition at screening and at 12- and 24-month follow-up visits. Five domains of cognition (immediate memory, visuospatial ability, language, attention and delayed memory) were assessed using 12 sub-tests. The RBANS takes approximately 30 minutes to administer and is a core diagnostic tool for detecting and characterising dementia (Randolph, Tierney, Mohr, & Chase, 1998). In the present study, a score of ≥78 was desirable for enrolment.
Specific domains of cognition were assessed using CANTAB Connect Research software (Cambridge Cognition, Cambridge, UK) (Zygouris & Tsolaki, 2015). This computerised software program was performed on an iPad and required a finger-operated response. The CANTAB protocol (Cambridge Cognition, 2016b) was followed in the administration of the test battery and was used to assess comprehension, executive function (working memory), reaction time and episodic memory (Cambridge Cognition, 2016a) at baseline and follow-up visits (see Table 1 for an overview of the CANTAB tests performed).
MOT task Performance ranges: the minimum and maximum possible score for each measure; Latency: the speed (milliseconds) of response to the stimulus; Total correct: the number of correct responses; Total errors: the distance between the centre of the cross and the location touched; SWM task Between errors: the number of times the individual revisits a box in which a token has previously been found; Total errors: the number of times a box is selected that is certain not to contain a token and therefore should not have been visited by the individual; Strategy: for problems with six boxes or more. The number of distinct boxes used by the individual to begin a new search for a token, with the same problem; RTI task Simple reaction time: the duration between the onset of the stimulus and the time at which the individual released the button. Calculated for correct trials, where the stimulus could appear in one location only; Simple movement time: the time taken to touch the stimulus after the button has been released. Calculated for correct trials, where the stimulus could appear in one location only; Simple error score: the number of trials where the response status is any error (i.e. an inaccurate response, no response, or a premature response) for the assessment trial where stimuli appear on one location only. The error may be an inaccurate response, no response, or a premature response; Five-choice reaction time: the duration between the onset of the stimulus and the release of the button. Calculated for correct, assessed trials where the stimulus could appear in any of the five locations; Five-choice movement time: the time taken to touch the stimulus after the button has been released. Calculated for correct, assessed trials where the stimulus could appear in any of the five locations; Five-choice error score: the number of trials where the response status is any error (i.e. an inaccurate response, no response, or a premature response) for assessment trials where stimuli appear in any of five locations; PAL task First attempt memory score: the number of correct box choices that were made on the first attempt during assessment problems; No. patterns reached: the number of patterns on the last problem reached in the task; Total errors adjusted: the number of times the individual chose the incorrect box for a stimulus on assessment problems, plus an adjustment for the estimated no. errors they would have made on any problems, attempts and recalls they did not reach.
MP was measured by dual-wavelength autofluorescence (AF) using the Spectralis HRA+OCT MultiColor (Heidelberg Engineering GmbH, Heidelberg, Germany). Details of MP acquisition were described previously. In brief, pupillary dilation was performed prior to measurement and patient details were entered into the Heidelberg Eye Explorer (HEYEX version 1.7.1.0) software. Using the HEYEX software, the movie images were aligned and averaged, and a MP density map was created. MPOV, calculated as MP average times the area under the curve out to 7° eccentricity, is reported here.
Carotenoid concentrations were also measured using the Pharmanex® BioPhotonic Scanner. This scanner measures carotenoid levels in human tissue at the skin surface using optical signals (resonant Raman spectroscopy). These signals identify the unique molecular structure of carotenoids, allowing their measurement without interference by other molecular substances. The individual was asked to place a specific point (between the maximal and distal palmar creases, directly below the fifth finger) of their right hand (previously cleaned with hand sanitiser) in front of the scanner's low-energy blue light for 30 seconds. From this, a skin carotenoid score was generated, which provided an indication of the individual's overall antioxidant levels. This was repeated twice more, and an average score was calculated. Based on this result an individual's score can be classified into three ranges; 0-29,000=low; 30,000-49,000=normal; 50,000+=high. This technology is safe and has been previously validated (Zidichouski, Mastaloudis, Poole, Reading, & Smidt, 2009).
The carotenoid standards L, Z, Z racemic mixture and b-cryptoxanthin were purchased from CaroteneNature (Lupsingen, Switzerland). DL-α-tocopherol was purchased to Merck Serono Ltd (Dublin, Ireland). Butylated hydroxyltoluene (BHT), α-tocopheryl acetate and HPLC grade heptane were purchased from Sigma-Aldrich (Arklow, Ireland). HPLC grade methyl tert-butyl ether (MTBE), water and isopropanol were supplied by Fisher Scientific (Dublin, Ireland). HPLC grade hexane and ethanol 96% were supplied by VWR (Dublin, Ireland). NIST SRM 968f was purchased to the National Institute of Standards and Technology (NIST, Gaithersburg, Md., US).
Non-fasting blood samples were collected at each study visit by standard venepuncture techniques. SST II Advance blood collection tubes (8.5 ml) were inverted at least 5 times to ensure thorough mixing of the silica clot activator. The blood samples were left to clot for 30 minutes at room temperature and then centrifuged at room temperature at 725 g for 10 minutes in a Gruppe GC12 centrifuge (Desaga Sarstedt, UK) to separate the serum from the whole blood. Following centrifugation, serum was transferred to light-resistant microtubes and stored at circa −80° C. until extraction. Xanthophyll carotenoids and α-tocopherol were extracted from serum samples and analysed by HPLC as previously described (Meagher et al. 2013).
HPLC solvents were used throughout the analysis. Methyl heneicosanoate, methyl docosanoate, methyl tricosanoate, EPA, DHA and the authentic Fatty acid methyl esters (FAME) standard Mixture ME 1220 were sourced from Larodan (Solna, Sweden). Methyl heneicosanoate, methyl docosanoate, methyl tricosanoate and EPA were used to prepare four calibration solutions with six concentrations in the range of 2.5-200 mg/L. Linearity was checked along the concentration range for each standard FAME, and the slope of each calibration line was used to obtain an average response factor (RF) of 0.157±0.012 mAU g L−1. Methyl heneicosanoate was used as recovery standard, and methyl tricosanoate was used to estimate matrix effect.
Lithium heparin blood collection tubes (6 ml) were inverted 8-10 times to ensure thorough mixing and centrifuged at 4° C. at 3000 rpm for 20 minutes in a 3-18K centrifuge (Sigma, Germany) to separate red blood cells and plasma. The time of blood collection and time of separation did not exceed 2 hours. Following centrifugation, all samples were transferred to light-resistant microtubes and stored at circa −80° C. until the time of analysis. Plasma ω-3FA analysis was performed by gas chromatography. FAME were prepared as previously described (Benner et al., 2018). Briefly, 50 μl of plasma were spiked with 20 μl of 2 mg/mL methyl tricosanoate and saponified with 2 mL of freshly prepared methanolic KOH 0.4 M during 10 min with gentle vortexing at room temperature. The samples were extracted three times with 2 mL of hexane and the combined extracts were dried in a vacuum centrifuge. The pellets were esterified with 2 mL of freshly prepared 5% methanolic sulfuric acid (v/v) at 80° C. for 30 min in a thermo-block. The FAME produced were extracted three times with 2 mL of hexane and dried in the vacuum centrifuge. The samples were resuspended in 0.4 mL of hexane containing 0.1 mg/mL of methyl heneicosanoate and prepared for GC-FID analysis. Methyl tricosanoete and methyl heneicosanoate 0.1 mg/mL were injected in triplicate to assess recovery and matrix effect respectively.
Best-corrected visual acuity (BCVA) was measured using a computerised Log MAR Early Treatment Diabetic Retinopathy Study (ETDRS) test chart (Test Chart 2000 Xpert; Thomson Software Solutions, Hatfield, UK) using the Sloan optotypes. Individuals were asked to read aloud the letters on the chart at a distance of 4 m. At the first incompletely read line, the letters of the line were randomised three times and an average score was calculated. BCVA was recorded in visual acuity rating (VAR). The eye with the best visual acuity was chosen as the study eye for assessment. Where both eyes had the same BCVA, the right eye was chosen.
Letter contrast sensitivity (CS) was measured for the study eye only using the computerised ETDRS test chart (Test Chart 2000 PRO) at five different spatial frequencies (1.2, 2.4, 6.0, 9.6, 15.15 cycles per degree [cpd]), using the Sloan optotypes. Individuals were asked to read letter aloud while fixating on the chart at a distance of 4 m. The letter set was randomised during the test at each change of contrast. The percentage contrast of letter optotypes is decreased in 0.15 log CS steps until the lowest contrast value for which subjects see at least three letters is reached. This process is then repeated for the remaining spatial frequencies. Each letter has a nominal log CS value of 0.03. Missed letters at any contrast level are noted. The resultant log CS value for the subject at a particular spatial frequency is calculated by adding any extra letter(s) and/or subtracting missed letters from best log CS value corresponding to the lowest percentage contrast.
Demographic, health and lifestyle data, medical history and current medication use were recorded via questionnaire. Height and weight measurements were recorded to calculate BMI (kg/m2). Smoking status was classified into never (smoked <100 cigarettes in lifetime), past (smoked ≥100 cigarettes in lifetime and none in the past year) or current smoker (smoked ≥100 cigarettes in lifetime and at least 1 cigarette in the last year). Alcohol consumption was measured in unit intake per week. One unit of alcohol (10 ml) was the equivalent to one of the following: a single measure of spirits (ABV 37.5%); half a pint of average-strength (4%) lager; two-thirds of a 125 ml glass of average-strength (12%) wine; half a 175 ml glass of average-strength (12%) wine; a third of a 250 ml glass of average-strength (12%) wine. Colour fundus photographs were taken to assess the presence of ocular pathology (Zeiss Visucam 200, Carl Zeiss Meditec AG, Jena, Germany).
The statistical package IBM SPSS version 25 was used and the 5% significance level applied for all analyses. Given that data were normally distributed, results were expressed as means±SD for numeric data. Categorical data were expressed as percentages. Between-group differences (i.e. active versus placebo) were analysed using Independent Samples t-tests or Chi-square tests as appropriate. The Monte Carlo Exact test was used where the assumption of the Chi-square tests were not met. rANOVA (repeated measures Analysis Of Variance) was used to assess Time-Group interaction effects across 3 time points (i.e. baseline, 12- and 24-month follow-up) between the active and placebo intervention groups for cognitive function, nutritional status and visual function variables. In cases where rANOVA showed interesting trends, further statistical analyses were conducted using paired samples t-tests to examine statistical difference within groups across beginning (i.e. at baseline) and end time points (i.e. at 24 months) for active and placebo intervention groups. A general linear model was used to assess (for dependent variables serum L, Z, MZ, and MP volume) the potential impact of sex, smoking habits, and alcohol consumption on Time and Time-Group effects. Finally, Spearman's rank correlation coefficient was used to investigate potential relationships between the observed changes in both cognitive and visual function and the observed changes in tissues and blood concentrations.
A sample size of 60 subjects was determined to be suitable in this study (with 30 subjects consuming the active supplement and 30 consuming placebo). Subjects were randomly allocated between the intervention groups and a 5% level of significance was chosen (i.e. a 95% confidence level). Calculations were based on rANOVA between two time points (i.e. baseline and end of study). All tests were assumed to be two-sided. RBANS across all five cognitive domains was an outcome measure for CARES. As all domains were considered to be of equal significance, the average scores were used for power analysis. Based on data provided from baseline, the mean RBANS score was 106 and mean standard deviation was 12. Assuming a correlation of 0.7 for within-subject RBANS scores between baseline and end of study, a statistical power of approximately 96% is estimated for an effect size of 10.6 (10% of baseline RBANS score) and 79% for an effect size of 7.95 (7.5% of RBANS score).
Baseline data for demographic, health and lifestyle, nutritional status, cognitive function and visual function are presented in Tables 2.1, 2.2, 2.3, and 2.4. All baseline variables were statistically comparable between both groups (p>0.05, for all). Of note, individuals (active n=5; placebo n=4) were excluded from analysis of CS 15.15 cpd as they recorded a baseline VAR of >90.
Data displayed are mean±SD for numeric data and percentages for categorical data. Education: age (years) completed formal education; BMI: body mass index; Medications: the number of prescribed medications consumed. Education data missing for 1 individual in the active intervention group.
Data displayed are mean±SD; MPOV: a volume of macular pigment calculated as macular pigment average times the area under the curve out to 7° eccentricity (measured using the Heidelberg Spectralis®); DHA: docosahexaenoic acid; EPA: eicosapentaenoic acid; Data missing in the active intervention group for the following variables: MPOV (n=1); skin carotenoid score (n=3); serum xanthophyll carotenoid and vitamin E concentrations (n=4); plasma DHA and EPA (n=3); serum xanthophyll carotenoid and vitamin E data missing for 1 individual in the placebo group.
Data displayed are mean±SD; MoCA: Montreal Cognitive Assessment; RBANS: Repeatable Battery for the Assessment of Neuropsychological Status; Data missing in the active intervention group for the following variables: 4MT score (n=8); SWM between errors stage 8 score (n=2); SWM between errors total score (n=1); SWM total errors stage 8 score (n=2); SWM total errors across all stages (n=1); SWM strategy score (n=1); Data missing in the placebo group for the following variables: 4MT score (n=4); SWM between errors stage 8 score (n=1); SWM total errors stage 8 score (n=1).
Data displayed are mean±SD; VAR: visual acuity rating; CS: contrast sensitivity. Data missing in the active intervention group for the following variables: VAR (n=1); CS 1.2 cpd (n=1); CS 2.4 cpd (n=1); CS 6 cpd (n=1); 9.6 cpd (n=1).
Of the 60 individuals enrolled at baseline, 9 were lost at follow-up. Among individuals in the active arm of the intervention trial, 2 were no longer interested in participating. Among individuals in the placebo arm of the intervention trial, 2 were no longer interested in participating, 2 developed early-stage age-related macular degeneration and 2 developed other health issues. One adverse event was recorded during the trial. One patient (female, aged 77 years at baseline) reported severe diarrhoea 4 weeks after commencing the trial. Of note, this patient was previously diagnosed with cancer of the rectum. Upon trial completion, details of the intervention code revealed that this subject was enrolled into the placebo arm of the intervention trial. Thus, an attrition rate of 15% was recorded for CARES.
Final visit (i.e. 24-month) data of 1 individual (male, aged 77 years at baseline) in the placebo arm of the intervention trial were removed prior to rANOVA analysis as MZ was detected in 24-month (but not 12-month) serum (0.186 μmol/L). The presence of MZ suggested carotenoid supplementation and was retrospectively confirmed via telephone with the individual.
Table 3 (and
The possibility of an interaction effect for sex, education, BMI, smoking status and alcohol consumption (units/week) on the statistically significant Time-Group effects observed for nutrition variables was examined using a general linear model. The dependent variables in these analyses included: MPOV; skin carotenoid score; serum L, Z MZ and vitamin E concentrations; and plasma DHA and EPA concentrations. No significant interactions were found (p>0.05, for all). Thus, for example, changes in MPOV did not differ by sex, BMI, smoking status nor alcohol consumption.
5399 ±1668
Table 4 and
Data displayed are mean±SD; % Δ at 12 months: 12-month visit minus baseline visit expressed as a percentage; % Δ at 24 months: 24-month visit minus baseline visit expressed as a percentage; Outcome: Interpretation of direction of result (i.e. improved or declined over time); T×G: Time×Group interaction effect; SWM TE8: spatial working memory total errors at stage 8, the number of times a box is selected that is certain not to contain a token and therefore should not have been visited by the individual at stage 8 of the assessment; SWM TE all stages: spatial working memory total errors across all stages, the number of times a box is selected that is certain not to contain a token and therefore should not have been visited by the individual, calculated across all stages of the assessment; RBANS: Repeatable Battery for the Assessment of Neuropsychological Status.
As noted previously, further statistical analyses were conducted in cases where rANOVA showed interesting trends. Paired samples t-tests were used to test statistical difference within groups across beginning and end time points for active and placebo intervention groups. Statistically significant improvements were observed among individuals in the active intervention group for executive function (between errors at stage 8 and total errors at stage 6) and simple reaction time (p<0.05, for all). Statistically significant improvements were observed in the RBANS total scale score for both groups (p=0.048 and p<0.001 for active and placebo groups, respectively) (see Table 5).
Data displayed are mean±SD; % Δ; 24-month visit minus baseline visit expressed as a percentage; SWM: spatial working memory; Simple reaction time: the duration between the onset of the stimulus and the time at which the individual released the button. Calculated for correct trials, where the stimulus could appear in one location only; Between errors: the number of times the individual revisits a box in which a token has previously been found; Total errors: the number of times a box is selected that is certain not to contain a token and therefore should not have been visited by the individual; RBANS: Repeatable Battery for the Assessment of Neuropsychological Status.
Over the 24-month intervention period, contrast sensitivity at 1.2 cpd and 2.4 cpd improved significantly (p<0.05, for both) in the active intervention group and was unchanged or declined in individuals consuming placebo (see Table 6 and
Data displayed are mean±SD; % Δ at 12 months: 12-month visit minus baseline visit expressed as a percentage; % Δ at 24 months: 24-month visit minus baseline visit expressed as a percentage; Outcome: Interpretation of direction of result (i.e. improved or declined over time); T×G: Time×Group interaction effect; VAR: visual acuity rating; CS: contrast sensitivity expressed in cycles per degree.
Data displayed are mean±SD; % Δ; 24-month visit minus baseline visit expressed as a percentage; VAR: visual acuity rating; CS: Contrast sensitivity expressed in cycles per degree.
Spearman's rank correlation coefficient was used to investigate whether or not the observed changes in cognitive scores were related to the observed changes in nutritional status (see Table 8 and
Observed change, exit visit data minus baseline visit data; MPOV, a volume of macular pigment calculated as macular pigment average times the area under the curve out to 7° eccentricity (measured using the Heidelberg Spectralis®); Serums lutein, zeaxanthin, meso-zeaxanthin carotenoid and vitamin E concentrations measured in μmol/L; Plasma docosahexaenoic acid and eicosapentaenoic acid concentrations measured in μmol/L; Total errors: the number of times a box is selected that is certain not to contain a token and therefore should not have been visited by the individual; Simple reaction time: the duration between the onset of the stimulus and the time at which the individual released the button. Calculated for correct trials, where the stimulus could appear in one location only.
The observed changes in CS at 1.2 cpd was positively and significantly related to the observed changes in serum L, serum MZ and plasma DHA concentrations (p<0.05, for all) (i.e. individuals with higher concentrations of these nutrients in blood had significantly better CS at 1.2 cpd than individuals with lower concentrations of these nutrients). Additionally, the observed change in CS at 9.6 cpd was also positively and significantly related to the observed change in MPOV and serum MZ concentrations (p<0.05, for both) (see Table 9 and
Observed change, exit visit data minus baseline visit data; CS: contrast sensitivity; MPOV, a volume of macular pigment calculated as macular pigment average times the area under the curve out to 7° eccentricity (measured using the Heidelberg Spectralis®); Serum lutein and meso-zeaxanthin and plasma docosahexaenoic acid concentrations measured in μmol/L.
The observed change in serum carotenoid concentrations (i.e. L, Z and MZ) were all, independently, positively and significantly related to the observed increases in MPOV and skin carotenoid concentrations (p<0.05, for all). Similarly, the observed change in plasma concentrations of DHA and EPA were both positively and significantly related to the observed change in MPOV and skin carotenoid concentrations (p<0.05, for both). Overall, the observed biochemical changes were positively and significantly related to the observed changes in tissue. Moreover, the observed changes in plasma concentrations of omega-3 fatty acids (DHA and EPA) were positively and significantly related to the observed changes in serum xanthophyll concentrations (L, Z and MZ) (p<0.05, for all). See Table 10 and
Observed change, exit visit data minus baseline visit data; CS: contrast sensitivity; MPOV, a volume of macular pigment calculated as macular pigment average times the area under the curve out to 7° eccentricity (measured using the Heidelberg Spectralis®); SCS: skin carotenoid score (measured using the Pharmanex BioPhotonic Scanner). Serums lutein, zeaxanthin, meso-zeaxanthin carotenoid and vitamin E concentrations measured in μmol/L; Plasma docosahexaenoic acid and eicosapentaenoic acid concentrations measured in μmol/L.
Statistically significant improvements in nutritional status (in blood and tissue) were observed in individuals that consumed a combination of xanthophyll carotenoids, ω-3 FAs and vitamin E for 24 months. Individuals in the active intervention also exhibited statistically significant improvements in vision and cognition. Specifically, individuals consuming this nutritional combination exhibited statistically significant improvements in executive function (working memory), attention and some domains of global cognition in comparison to individuals consuming placebo. Moreover, the magnitude of change in nutritional status observed in both blood and tissue was directed related to the magnitude of change observed in cognitive and visual function.
With specific reference to measures of executive function, individuals in the active arm of the trial made significantly fewer errors at the final stage (stage 8) of the SWM test, and significantly fewer errors across all stages than individuals receiving placebo. Strikingly, the observed changes in blood and tissue concentrations of these particular nutrients were directly related to the observed improvements in this task.
In the present study, the encoding and retrieval of information was comparable between both active (errors at baseline=0.93; errors at final visit=0.86) and placebo groups (errors at baseline=0.80; errors at final visit=0.30) (p=0.797) during a working memory task with few stimuli (i.e. stage 4 of the SWM task where the individual had to locate 4 tokens). However, as the cognitive load increased (e.g. from 4 to 6 tokens), individuals in the active intervention (errors at baseline=4.50; errors at final visit=2.27) outperformed individuals in the placebo group (errors at baseline=4.26; errors at final visit=4.74) (p=0.072), with significantly better performance in the latter (i.e. stage 8) and total stages (p<0.05, for both) of the SWM task (see Table 4), where the cognitive load was at its highest. This suggests that the working memory capacity of individuals was favourably altered over time and that these positive changes may be attributed to the enrichment of specific nutrients in blood and tissue, given that the magnitude of change in nutritional status was related to the magnitude of change in cognitive function.
An additional and important finding from CARES Trial relates to the positive and significant relationships observed between tissue and blood concentrations of the specific nutrients tested in the intervention trial. The results suggest that the presence of ω-3 FAs in blood improved the biochemical response of the xanthophyll carotenoids, which in turn improved their respective concentrations in tissue. This improved delivery of these nutrients is likely to have contributed to the observed improvements in cognitive and visual function, thus supporting a plausible rationale for consumption of these nutrients in combination with one another for cognitive (and indeed ocular) health. The present study also relates the observed changes in blood and tissues to measures of function, primarily working memory and contrast sensitivity. It is possible that the interaction between xanthophyll carotenoids and ω-3 FAs is due to the hydrophobic nature of the xanthophylls, as it is known that consuming foods rich in carotenoids in the presence of oils or cholesterol can facilitate the uptake and bio-accessibility of carotenoids (van het Hof, et al., 2000).
While individuals in the active intervention group responded to nutritional supplementation in terms of statistically significant improvements in serum xanthophyll carotenoid levels and plasma ω-3 FA levels, significant improvements were not observed for serum concentrations of α-tocopherol. Reasons underlying the poor vitamin E response following supplementation remain unclear. However, it is possible that circulating levels of vitamin E were sufficiently high at baseline and that additional amounts of vitamin E were not needed and thus excreted. In a national survey of almost 1,200 individuals aged 18+ years, circulating vitamin E concentrations in blood were reported as 32.04 μmol/L (approx. 13.8 mg) (Zhao et al., 2014). Given that a large amount of vitamin E is already present in blood in comparison to carotenoids for example, it is likely that the amount of α-tocopherol provided in the CARES supplement was insufficient to have any meaningful effect on circulating vitamin E levels in blood.
In conclusion, the inventors have shown improvements in working memory, attention, domains of global cognition and measures of CS following 24-month supplementation with a combination of xanthophyll carotenoids (L, Z, MZ), ω-3 FAs (DHA, EPA) and vitamin E. The observed functional improvements were directly related to the observed increases of these nutrients (except vitamin E) in blood and tissue. The results suggest that the presence of ω-3 FAs in blood improved the biochemical response of the xanthophyll carotenoids, which in turn improved their respective concentrations in tissue and positively impacted on function. These results support a plausible rationale whereby these nutrients work together to optimise the neuro-cognitive environment. These findings have important implications for older adults in terms of enabling individuals to continue to function independently and interact with their environment in a meaningful way.
As the present invention may be embodied in several forms without departing from the spirit or essential characteristics thereof, it will be understood that the invention is not limited by the details of the foregoing description, unless otherwise specified, but rather should be construed broadly within its spirit and scope as defined in the appended claims, and therefore all changes and modifications that fall within the metes and bounds of the claims. Accordingly, the invention is defined by the appended claims.
This application is a continuation-in-part of U.S. application Ser. No. 16/426,771, filed May 30, 2019, which is a continuation-in-part of U.S. application Ser. No. 15/980,083, filed May 15, 2018 in the U.S. Patent and Trademark Office. This application claims the benefit of United Kingdom Application No. 1915485.5, filed Oct. 25, 2019, and United Kingdom Application No. 1720119.5, filed Dec. 4, 2017 in the United Kingdom Intellectual Property Office. All disclosures of the documents named above are incorporated herein by reference.
| Number | Date | Country | |
|---|---|---|---|
| Parent | 16426771 | May 2019 | US |
| Child | 16795058 | US | |
| Parent | 15980083 | May 2018 | US |
| Child | 16426771 | US |
